Your browser doesn't support javascript.
loading
Clinicopathologic characteristics and prognostic factors in patients with male breast cancer: A single tertiary center experience.
Dogan, Izzet; Aydin, Esra; Ak, Naziye; Ozkurt, Selnur; Ibis, Kamuran; Sükrüoglu, Ozge; Erciyas, Seda Kilic; Küçücük, Seden; Yazici, Hulya; Aydiner, Adnan; Saip, Pinar.
Affiliation
  • Dogan I; Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
  • Aydin E; Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
  • Ak N; Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
  • Ozkurt S; Department of Radiation Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
  • Ibis K; Department of Radiation Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
  • Sükrüoglu O; Department of Cancer Genetics, Istanbul University Institute of Oncology, Istanbul, Turkey.
  • Erciyas SK; Department of Cancer Genetics, Istanbul University Institute of Oncology, Istanbul, Turkey.
  • Küçücük S; Department of Radiation Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
  • Yazici H; Department of Cancer Genetics, Istanbul University Institute of Oncology, Istanbul, Turkey.
  • Aydiner A; Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
  • Saip P; Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
J Cancer Res Ther ; 19(7): 1887-1892, 2023 Oct 01.
Article in En | MEDLINE | ID: mdl-38376293
ABSTRACT

BACKGROUND:

The goal of this study was to assess the clinicopathologic characteristics and prognostic variables in men with breast cancer (BC).

METHODS:

Clinical features, pathological characteristics, stage at diagnosis, and therapy data were noted. Survival analysis was performed using the log-rank technique and Cox regression model.

RESULTS:

Eighty patients were included in the study. In 31% of the individuals, BRCA (BReast CAncer genes 1 and 2) mutations were identified. The estrogen receptor (ER) positivity ratio was 93.6%, whereas the progesterone receptor (PR) positivity ratio was 74.4%. In 16.9% of the cases, HER2 overexpression was found. The median survival time was 120.9 months (70.3-171.5), and the five-year overall survival (OS) ratio was 74.9%. In univariate analysis, BRCA mutation status had no effect on OS (P = 0.50). CA15-3 levels (P = 0.03) at diagnosis and history of smoking (P = 0.03) were significantly linked with OS. However, the multivariate analysis could not confirm these results.

CONCLUSIONS:

We found that BRCA mutation, body mass index, a history of smoking, and alcohol consumption did not affect the OS in this research.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms, Male Limits: Humans / Male Language: En Journal: J Cancer Res Ther Journal subject: NEOPLASIAS / TERAPEUTICA Year: 2023 Document type: Article Affiliation country: Turquía Country of publication: India

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms, Male Limits: Humans / Male Language: En Journal: J Cancer Res Ther Journal subject: NEOPLASIAS / TERAPEUTICA Year: 2023 Document type: Article Affiliation country: Turquía Country of publication: India